Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Molecular Partners Ag (MOLN) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Molecular Partners Ag (MOLN) over the last 5 years, with Q3 2025 value amounting to 168555835.43%.

  • Molecular Partners Ag's EBITDA Margin fell 1685536931400.0% to 168555835.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 263599.18%, marking a year-over-year decrease of 2625683100.0%. This contributed to the annual value of 0.0% for FY2024, which is 8728600.0% down from last year.
  • As of Q3 2025, Molecular Partners Ag's EBITDA Margin stood at 168555835.43%, which was down 1685536931400.0% from 1431.03% recorded in Q1 2025.
  • Over the past 5 years, Molecular Partners Ag's EBITDA Margin peaked at 486415.0% during Q4 2021, and registered a low of 168555835.43% during Q3 2025.
  • For the 5-year period, Molecular Partners Ag's EBITDA Margin averaged around 9338021.62%, with its median value being 600.34% (2022).
  • In the last 5 years, Molecular Partners Ag's EBITDA Margin surged by 27971800bps in 2024 and then tumbled by 2000000000bps in 2025.
  • Quarter analysis of 5 years shows Molecular Partners Ag's EBITDA Margin stood at 486415.0% in 2021, then crashed by -100bps to 61.5% in 2022, then crashed by -1307bps to 742.14% in 2023, then surged by 100bps to 0.93% in 2024, then tumbled by 2000000000bps to 168555835.43% in 2025.
  • Its EBITDA Margin stands at 168555835.43% for Q3 2025, versus 1431.03% for Q1 2025 and 0.93% for Q4 2024.